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Seven commercial assays were evaluated to determine their suitability for the diagnosis of acute dengue infection: (i) the
Panbio dengue virus Pan-E NS1 early enzyme-linked immunosorbent assay (ELISA), second generation (Alere, Australia);
(ii) the Panbio dengue virus IgM capture ELISA (Alere, Australia); (iii) the Panbio dengue virus IgG capture ELISA (Alere,
Australia); (iv) the Standard Diagnostics dengue virus NS1 antigen ELISA (Standard Diagnostics, South Korea); (v) the
Standard Diagnostics dengue virus IgM ELISA (Standard Diagnostics, South Korea); (vi) the Standard Diagnostics dengue
virus IgG ELISA (Standard Diagnostics, South Korea); and (vii) the Platelia NS1 antigen ELISA (Bio-Rad, France). Samples
from 239 Thai patients confirmed to be dengue virus positive and 98 Sri Lankan patients negative for dengue virus infec-
tion were tested. The sensitivities and specificities of the NS1 antigen ELISAs ranged from 45 to 57% and 93 to 100% and
those of the IgM antibody ELISAs ranged from 85 to 89% and 88 to 100%, respectively. Combining the NS1 antigen and
IgM antibody results from the Standard Diagnostics ELISAs gave the best compromise between sensitivity and specificity
(87 and 96%, respectively), as well as providing the best sensitivity for patients presenting at different times after fever on-
set. The Panbio IgG capture ELISA correctly classified 67% of secondary dengue infection cases. This study provides strong
evidence of the value of combining dengue virus antigen- and antibody-based test results in the ELISA format for the diag-
nosis of acute dengue infection.
Dengue virus is an important cause of acute febrile illness intropical and subtropical settings, with clinical manifesta-
tions of infection ranging from the more mild form of dengue
fever (DF) to the more severe forms of dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS). Diagnosis of
acute dengue infection using clinical signs and symptoms is
complicated by the wide range of possibilities for differential
diagnosis, and therefore, laboratory assays are normally relied
upon to make a diagnosis. While point-of-care tests for dengue
infection have improved markedly in recent times (4, 23), in-
house and commercial enzyme-linked immunosorbent assays
(ELISAs) are often relied upon for a final diagnosis. Dengue
virus ELISAs have been designed for the detection of nonstruc-
tural 1 (NS1) antigen and IgM and IgG antibodies, and the
major commercial manufacturers are Panbio, Standard Diag-
nostics, and Bio-Rad. Recent studies have compared ELISAs
from individual companies (17) or have compared limited
combinations of ELISAs from different companies (12, 13, 19);
however, there is a paucity of studies that have compared the
diagnostic performances of all NS1, IgM, and IgG ELISAs from
the three major manufacturers.
In this study, we evaluated seven commercial dengue virus
ELISAs fromPanbio, StandardDiagnostics, andBio-Rad head-to-
head for (i) the diagnosis of acute dengue infection and (ii) the
determination of dengue infection status using gold standard, ref-
erence-characterized dengue virus-positive and -negative samples
from Thailand and Sri Lanka.
MATERIALS AND METHODS
Assays. Seven assays were evaluated: (i) the Panbio dengue virus Pan-E
NS1 early ELISA, second generation (Alere, Australia); (ii) the Panbio
dengue virus IgM capture ELISA (Alere, Australia); (iii) the Panbio den-
gue virus IgG capture ELISA (Alere, Australia); (iv) the Standard Diag-
nostics dengue virus NS1 antigen ELISA (Standard Diagnostics Inc.,
South Korea); (v) the Standard Diagnostics dengue virus IgM ELISA
(Standard Diagnostics Inc., South Korea); (vi) the Standard Diagnostics
dengue virus IgG ELISA (Standard Diagnostics Inc., South Korea); and
(vii) the Platelia NS1 antigen ELISA (Bio-Rad, France). A summary of
assay characteristics is presented in Table 1. All assays were performed
according to the manufacturers’ instructions at the Mahidol University-
Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand.
Samples. In order to define the sensitivities and specificities of the
ELISAs, a case-control design using reference-characterized dengue virus-
positive and -negative serum samples was employed (Table 2). Reference
dengue virus-positive samples were previously characterized paired ad-
mission and discharge serum collections (i.e., admission and discharge
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samples [n  478] from 239 patients) (3), depersonalized and anony-
mized, from diagnostic specimens collected in 2003 from pediatric pa-
tients with dengue infection and were provided by the Armed Forces
Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.
Dengue virus (DEN) and Japanese encephalitis virus (JEV) reference as-
says were performed at AFRIMS. Only dengue fever patients, classified
using the World Heath Organization 1997 dengue classification scheme
(6, 26), were included in the study. Dengue virus infections were con-
firmed on an individual patient basis by using the results for paired ad-
mission and discharge specimens tested by the AFRIMS dengue virus IgM
antibody capture (MAC) and IgG antibody capture (GAC) ELISAs and
equivalent JEV assays (JEVMAC and GAC ELISAs) (14) with the follow-
ing interpretations (Fig. 1). For paired specimens, an increase in the DEN
MAC ELISA result from15 U of IgM in the admission sample to30 U
in the discharge specimen was considered evidence of an acute primary
dengue virus infection. Patients with DENMAC ELISA results of40 U
and JEVMAC ELISA results of40 U were classified as having acute JEV
infection. If a patient was positive for dengue virus and JEV, the ratio of
anti-dengue virus to anti-JEV IgM antibodies was used, with a ratio of1
interpreted to indicate positivity for dengue virus and a ratio of1 inter-
preted to indicate positivity for JEV. In the absence of DEN MAC ELISA
results of 40 U for the admission specimen, a 2-fold rise in DEN GAC
ELISA results to a value of100 U was indicative of a secondary or later
dengue virus infection. A dengue virus reverse transcriptase PCR (RT-
PCR) (15, 16) was used to determine the serotype identity, but these
results were not used as part of the AFRIMS diagnostic algorithm. Infor-
mation on the number of days of illness prior to admission sample collec-
tion was not available; however, the median number of days between the
admission and discharge collections was 5, with an interquartile range of
4 to 7 days. The dengue virus serotype was determined in 70.3% of cases
(168 of 239), with the following results: serotype 1, 56.0% of cases (94 of
168), serotype 2, 23.2% of cases (39 of 168), serotype 3, 9.5% of cases (15
of 168), and serotype 4, 11.9% of cases (20 of 168). On the basis of refer-
ence serology for patients with paired specimens for whom the infection
status could be determined, 14.2% of patients (33) had primary dengue
infection and 87.8% (199) had secondary infection.
Dengue virus-negative patient samples (n  98) (Table 2) were col-
lected during the Ragama Fever Study conducted at the North Colombo
Teaching Hospital, Sri Lanka, from June 2006 to June 2007 with a cohort
of adult febrile patients (ages,16 years; temperatures,38°C) (4). Bac-
teremia cases (n 17) were identified by hemoculture. Chikungunya cases
(n  35) were identified at AFRIMS by the hemagglutination inhibition
method with a 1:10 dilution, as well as by in-house IgM antibody capture
ELISAs (14) and RT-PCR analysis (15, 16). Cases of scrub typhus (n  7;
identified at MORU) and Q fever (n  6) were detected using an indirect
microimmunofluorescence assay (22) tomeasure a 4-fold (or greater) rise in
titer between paired specimens. Leptospirosis cases (n 33) were identified
by in vitro isolation of Leptospira organisms in Ellinghausen-McCullough-
Johnson-Harris (EMJH) medium or gold standard microagglutination test
serology. All samples from the Sri Lankan cohort were also determined to be
negative for dengue virus IgM and IgG antibodies following testing using the
above-describedAFRIMSELISAs. Samples (n50) fromhealthy individuals
were derived from blood donors at the Queen Sirikit National Institute of
Child Health in Bangkok, Thailand.
Analysis. Diagnostic accuracy was calculated for each ELISA relative
to the final patient diagnostic status (i.e., dengue virus positive or dengue
virus negative) based on the results of AFRIMS reference serology. Diag-
nostic accuracy indices were calculated for sensitivity and specificity with
exact 95%confidence intervals (CI) for admission samples (tested forNS1
antigen and IgM and IgG antibodies) and discharge specimens (tested for
IgM and IgG antibodies). Significant differences (P  0.05) in ELISA
positivity rates relative to dengue virus serotypes were calculated using
Pearson’s chi-square test or Fisher’s exact test. Medians and interquartile
(IQR) ranges for the number of days of fever were calculated where the
data were available. All statistics were calculated using Stata/SE 10.0 (Stata
Corp., College Station, TX).
Practical assessment of diagnostic utility. In order to examine and
compare the true diagnostic utilities of the dengue virus IgM and IgG
antibody and NS1 antigen ELISAs for dengue diagnosis upon admission,
the following questions were posed.
(i) In a patient presenting with suspected acute dengue virus infection,
how accurate are the IgM and IgG antibody orNS1 antigen ELISAs for the
diagnosis of dengue virus infection?
(ii) In a patient presenting with suspected acute dengue virus infec-
tion, how accurate are IgM and IgG antibody ELISAs for the identification
of primary and secondary dengue virus infection?
(iii) Is there any difference in ELISA accuracy among different dengue
virus serotypes?
TABLE 1 Characteristics of selected dengue virus ELISAsa
Manufacturer Product name Catalogue no. Lot no. Analyte
Quoted accuracy
(Sn/Spb)
Sample
typec
Differentiation of
primary and
secondary
infectionsd
Sample vol
(l)
(dilution
ratio)
Standard
Diagnostics
Dengue virus NS1 ELISA 11EK50 RET9002 NS1 antigen 92.7/98.4 S No 50 (1:2)
Dengue virus IgM ELISA 11EK20 217007-1 IgM 96.4/98.9 (Sn for primary
infection, 90.0; Sn for
secondary infection,
96.9)
S No 10 (1:100)
Dengue virus IgG ELISA 11EK10 216004 IgG 98.8/99.2 (Sn for primary
infection, 100; Sn for
secondary infection,
98.7)
S No 10 (1:100)
Alere Panbio dengue virus Pan-E early
ELISA (second generation)
E-DEN02P 09027 NS1 antigen Study 1, 77.7/93.6; study
2, 76.0/98.4
S No 75 (1:2)
Panbio dengue virus IgM
capture ELISA
E-DEN02M Not known IgM Sn for primary infection,
94.7; Sn for secondary
infection, 55.7/Sp, 100
S No 10 (1:100)
Panbio dengue virus IgG capture
ELISA
E-DEN02G 09080 IgG Study 1, 96.3/91.4
(secondary infection);
study 2, 80.9/87.1
(secondary infection)
S Yes 10 (1:100)
Bio-Rad Platelia NS1 antigen assay 72830 9K1023 NS1 antigen 91/100 S or P No 50 (1:2)
a For each assay, standard marks are European Conformity/In Vitro Diagnostics (CE/IVD) marks, and sample storage temperatures are 2 to 8°C.
b Sn/Sp, sensitivity/specificity. Values are expressed as percentages.
c S, serum; P, plasma.
d Based on manufacturer claims of ELISA capabilities.
ELISA Dengue Diagnosis
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RESULTS
ELISA accuracy and utility questions. (i) In a patient presenting
with suspected acute dengue virus infection, how accurate are
the IgM and IgG antibody or NS1 antigen ELISAs for the diag-
nosis of dengue virus infection? For diagnosis using admission
samples, the sensitivities and specificities of the Standard Diag-
nostics, Bio-Rad Platelia, and Panbio Pan-E NS1 antigen assays
ranged from 44.8% (Panbio) to 56.5% (Bio-Rad) and 93.2%
(Panbio) to 100% (Bio-Rad), respectively (Table 3). For IgM
antibody detection, the sensitivities and specificities of the Stan-
TABLE 2 Description of specimens used in this study
Infection status
No. of
patients
No. of
samples
Patient
origin
No. of patients admitted with:
Verification method(s)
Primary
dengue
virus
infection
Secondary
dengue
virus
infection
Undetermined
infection statusb
Positive for infection with dengue
virus serotype:
1 94 187 Thailand 16 73 5 RT-PCR and IgM/IgG ELISA
2 39 78 Thailand 1 38 0 RT-PCR and IgM/IgG ELISA
3 15 30 Thailand 3 11 1 RT-PCR and IgM/IgG ELISA
4 20 40 Thailand 0 20 0 RT-PCR and IgM/IgG ELISA
Undetermineda 71 142 Thailand 13 57 1 IgM/IgG ELISA
Subtotal 239 478 33 199 7
Negative for dengue virus infection
and positive for:
Chikungunya fever 35 35 Sri Lanka RT-PCR and IgM ELISA
Leptospirosis 33 33 Sri Lanka Culture
Bacteremia 17 17 Sri Lanka Hemoculture
Scrub typhus 7 7 Sri Lanka IgM immunofluorescence analysis
Q fever 6 6 Sri Lanka IgM immunofluorescence analysis
Healthy donorc 50 50 Thailand
Subtotal 148 148
Total 387 626
a Patient was PCR negative.
b Only the admission sample was collected; hence, primary or secondary infection status cannot be accurately determined.
c Data are for healthy blood donors.
FIG 1 Flow chart detailing the AFRIMS dengue diagnostic algorithm.
Blacksell et al.
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dardDiagnostics and Panbio tests were 74.4 and 83.2%, respec-
tively, and 97.3 and 87.8%, respectively, and for IgG antibody
detection, they were 81.2 and 39.8%, respectively, and 63.5 and
95.3%, respectively (Table 3). All Standard Diagnostics and
Panbio IgM and IgG ELISAs gave higher sensitivity results with
discharge samples than with matching admission samples (Ta-
ble 3). Combining the NS1 antigen and IgM antibody results
from assays from the same manufacturer gave overall sensitiv-
ities and specificities of 87.4 and 95.5% for the Standard Diag-
nostics NS1 antigen and IgM antibody tests and 87.9 and 84.5%
for the Panbio Pan-E NS1 antigen and IgM antibody capture
ELISAs.
The ELISAs that gave the highest percentages of false-positive
results were the Standard Diagnostics IgG ELISA (positive for
36.5% of dengue virus-negative patients), the Panbio IgM capture
ELISA (positive for 12.2% of dengue virus-negative patients), and
the Panbio Pan-E NS1 ELISA (positive for 8.1% of dengue virus-
negative patients) (Table 4). The Standard Diagnostics IgG ELISA
TABLE 3 Overall levels of diagnostic accuracy and sensitivity for seven ELISAs by dengue virus serotypea
Assay(s)
% sensitivity (95% confidence interval) for:
% specificity
(95% confidence
interval)b
No.c (%) positive for serotype:
P value
(Fisher’s
exact test)
Admission
samples
(n 239)
Discharge
samples
(n 239)
All samples
(n 626) 1 (n 94) 2 (n 39) 3 (n 15) 4 (n 20)
Undeterminedd
(n 71)
Dengue NS1 detection
ELISAs
Panbio
second-generation
44.8 (38–51) ND 44.8 (38–51) 93.2 (88–97) 47 (50) 23 (59) 7 (47) 6 (30) 24 (34) 0.213
Standard Diagnostics 55.2 (49–62) ND 55.2 (49–62) 98.6 (95–100) 67 (71) 16 (41) 11 (73) 8 (40) 30 (42) 0.002
Bio-Rad 56.5 (50–63) ND 56.5 (50–63) 100 (98–100) 66 (70) 15 (38) 11 (73) 11 (55) 32 (45) 0.005
Dengue IgM detection
ELISAs
Panbio 83.2 (78–87) 93.7 (90–96) 88.6 (86–91) 87.8 (82–93) 86 (91) 28 (72) 12 (80) 14 (70) 59 (83) 0.007
Standard Diagnostics 74.4 (69–80) 95.0 (91–97) 84.9 (81–88) 97.3 (93–99) 73 (78) 27 (69) 12 (80) 11 (55) 55 (78) 0.178
Dengue IgG detection
ELISAs
Panbio 39.8 (4–46) 72.8 (67–78) 56.4 (52–61) 95.3 (91–98) 31 (44) 36 (38) 14 (36) 4 (27) 10 (50) 0.564
Standard Diagnostics 81.2 (76–86) 96.2 (93–98) 88.9 (86–92) 63.5 (55–71) 62 (87) 71 (76) 34 (87) 9 (60) 18 (90) 0.086
Combined dengue IgM
antibody and NS1
antigen detection
ELISAs
Panbio 87.9 (83–92) ND 87.9 (83–92) 84.5 (78–90) 90 (96) 32 (82) 13 (87) 15 (75) 60 (85) 0.006
Standard Diagnostics 87.4 (83–91) ND 87.4 (83–91) 95.6 (91–99) 89 (95) 30 (76) 13 (87) 15 (75) 62 (87) 0.005
a Samples from patients with confirmed dengue virus infections and patients negative for dengue virus were tested. ND, not determined.
b Specificity for samples taken at admission from patients with dengue virus infection and samples from dengue virus-negative patients (n 387).
c Total numbers of positive patients are given as n values.
d The serotype could not be determined because samples were PCR negative and serology positive.
TABLE 4 Numbers of false-positive ELISA results for patients with reference test-confirmed non-dengue virus infectionsa
Assay(s)
No. of false-positive results for patients with:
No. of false-positive
results for healthy
donors (n 50)
Total no. (%) of false
positives among 148
samples
Chikungunya
fever (n 35)
Leptospirosis
(n 33)
Bacteremia
(n 17)
Scrub typhus
(n 7)
Q fever
(n 6)
Dengue NS1 detection ELISAs
Panbio second-generation 3 1 2 3 1 2 12 (8.1)
Standard Diagnostics 1 0 0 1 0 0 2 (1.4)
Bio-Rad 0 0 0 0 0 0 0
Dengue IgM detection ELISAs
Panbio 2 3 2 4 1 6 18 (12.2)
Standard Diagnostics 1 1 0 0 1 1 4 (2.7)
AFRIMS (cutoff,40
U of IgM)
0 0 0 0 0 0 0
Dengue IgG detection ELISAs
Panbio 3 0 0 0 1 3 7 (4.7)
Standard Diagnostics 21 6 4 2 3 18 54 (36.5)
AFRIMS (cutoff,100
U of IgG)
1 0 0 0 0 0 1 (0.7)
a Numbers of samples tested are given as n values.
ELISA Dengue Diagnosis
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demonstrated positivity with samples from chikungunya (21),
leptospirosis (6), scrub typhus (2), Q fever (3), and bacteremia (4)
patients and healthy blood donors (18). The Panbio Pan-E NS1
antigen ELISA demonstrated positivity with samples from chi-
kungunya (3), leptospirosis (1), scrub typhus (3), Q fever (1), and
bacteremia (2) patients and blood donors (2), and the Panbio IgM
capture ELISA demonstrated positivity with samples from chi-
kungunya (2), leptospirosis (3), scrub typhus (4), Q fever (1), and
bacteremia (2) patients and blood donors (6).
Levels of agreement with AFRIMS reference assays (RT-PCR,
the DENMACELISA, and theDENGACELISA) were compared.
Between NS1 ELISAs and RT-PCR, levels of agreement were
54.4% (for the Panbio assay), 59.4% (for the Bio-Rad assay), and
59.8% (for the Standard Diagnostics assay); between IgM ELISAs
and theDENMACELISA, levels of agreementwere 71.5% (for the
Panbio assay) and 77.0% (for the StandardDiagnostics assay); and
between IgG ELISAs and the DEN GAC ELISA, levels of agree-
ment were 59.3% (for the Standard Diagnostics assay) and 81.7%
(for the Panbio assay).
(ii) In a patient presentingwith suspected acute dengue virus
infection, how accurate are IgM and IgG antibody ELISAs for
the identification of primary and secondary dengue virus infec-
tion? Only the Panbio IgG capture ELISA claimed to be able to
discriminate between primary and secondary dengue infections.
Overall, the Panbio IgG capture ELISA was able to correctly diag-
nose 66.6% of secondary infections (263 of 395), in 47.2% of ad-
mission samples (94 of 199) and 86.2% of discharge samples (169
of 196).
(iii) Is there any difference in ELISA accuracy among differ-
ent dengue virus serotypes? The proportions of dengue virus se-
rotype positivity for each ELISA are presented in Table 3. Percent-
ages of positive results for the Panbio NS1 ELISA ranged from
30% (serotype 4) to 59% (serotype 2), those for the Standard
Diagnostics NS1 ELISA ranged from 40% (serotype 4) to 71%
(serotype 1), and those for the Bio-Rad NS1 ELISA ranged from
38% (serotype 2) to 73% (serotype 3). Percentages of positive
results for the Panbio IgMELISA ranged from70% (serotype 4) to
91% (serotype 1), and those for the Standard Diagnostics IgM
ELISA ranged from 55% (serotype 4) to 80% (serotype 3). Per-
centages of positive results for the Panbio IgG ELISA ranged from
27% (serotype 4) to 44% (serotype 1), and those for the Standard
Diagnostics IgG ELISA ranged from 60% (serotype 4) to 87%
(serotypes 1 and 3). The Standard Diagnostics NS1 (P  0.002),
Bio-Rad Platelia NS1 (P 0.005), and Panbio IgM capture (P
0.007) ELISAs, as well as both the Panbio (P  0.006) and the
Standard Diagnostics (P  0.005) NS1/IgM assay combinations,
demonstrated significant differences in positivity among dengue
virus serotypes. The combined Standard Diagnostics NS1/IgM
ELISAs and the Panbio NS1/IgM ELISAs gave almost identical
results, correctly detecting between 96% (serotype 1) and 75%
(serotype 4) of infections.
DISCUSSION
We evaluated seven commercially available ELISAs that detect
IgM and IgG antibodies and NS1 antigen, individually or in com-
bination, for the diagnosis of acute dengue infections using pa-
tient samples from settings in Thailand and Sri Lanka where den-
gue is endemic. Our results are the first head-to-head evaluation
of all contemporary dengue ELISAs from the three major com-
mercial diagnostic test manufacturers for both antigen and anti-
body detection.
Recent studies have demonstrated the benefits of combining
NS1 antigen and IgM antibody results for the diagnosis of dengue
infections (2, 11, 19). NS1 antigen is detectable by commercial
ELISAs in the first 7 to 9 days of infection, and IgM antibodies are
detectable only after 4 to 5 days of infection (7, 11, 12); combining
NS1 and IgM results allows for dengue diagnosis throughout the
normal temporal spectrum of patient presentation. This study has
highlighted that the detection of a single analyte, NS1 antigen or
IgM or IgG antibodies alone, does not provide sufficient accuracy
for the diagnosis of dengue infections and that the combination of
NS1 antigen and IgM antibody testing provides the ideal balance
of high sensitivity and specificity. It is important that diagnosti-
cians and clinicians are aware of this and the limitations of the
individual assays.
The Panbio Pan-E NS1 antigen and IgM capture antibody
ELISAs demonstrated lower specificity than other assays exam-
ined in this study. Standard Diagnostics and Bio-Rad Platelia NS1
antigen assays gave similar levels of performance, with high levels
of specificity but just over 50% sensitivity for the detection of
acute dengue infections. Similar to a previous study (12), the pres-
ent study found that the Panbio Pan-E NS1 antigen ELISA gave
poor sensitivity and a surprisingly high number of false-positive
results for dengue virus-negative patient samples compared to the
other NS1 assays.
The Panbio IgM capture ELISA showed approximately 10%
higher sensitivity than the Standard Diagnostics IgM ELISA, al-
though specificity was approximately 10% lower. When the Pan-
bio and Standard Diagnostics NS1 antigen and IgM antibody re-
sults were combined on a per-manufacturer basis, the sensitivities
were almost identical; however, the Panbio combination had ap-
proximately 10% lower specificity. Results presented here are sim-
ilar to those fromprevious studies that combinedNS1 antigen and
IgM antibody results from Standard Diagnostics assays (sensitiv-
ity, 78%; specificity, 91%) (19) and from Panbio assays (sensitiv-
ity, 78%; specificity, 84%) (5), albeit the results presented in this
study include slightly higher sensitivities.
This study has clearly demonstrated the poor diagnostic value
of IgG alone for acute dengue diagnosis. While the Standard Di-
agnostics IgG ELISA demonstrated high levels of sensitivity for
admission samples, it had poor specificity, possibly because of
patients’ previous dengue infections. The Panbio IgG capture
ELISA demonstrated higher specificity but poor admission sam-
ple sensitivity. However, the manufacturers of the Panbio IgG
capture ELISA claim that the assay was specifically designed for
the detection of secondary dengue infections: 67% of secondary
infectionswere detected, although only 47%of admission samples
were positive, a proportion which rose to an acceptable level of
86% of discharge samples.
While all assays detected all four dengue virus serotypes in
various proportions, five of the seven assays demonstrated statis-
tically significant differences in positivity for the different sero-
types. However, this appears to be of little practical significance
given that all serotypes were detected with reasonable reliability
when NS1 antigen and IgM antibody results were combined. Pre-
vious studies examining variation in serotype detection by the
Standard Diagnostics (24) and Panbio/Bio-Rad Platelia (12) NS1
ELISAs reported generally higher sensitivities than those pre-
sented here. Interestingly, the Bio-Rad and Standard Diagnostics
Blacksell et al.
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NS1 antigen ELISAs had relatively low sensitivities for dengue
virus serotype 2 compared to previously reported sensitivities of
the Bio-Rad assay for the other serotypes (7), which is significant
as serotype 2 is highly prevalent in both the Americas and Asia (1,
8, 10, 21).
A number of potential limitations to this study are related to
the choice of samples. The samples used here were selected as case
or noncase samples, with a predominance of dengue case samples
(61.2%, corresponding to 239 of 387 patients). The prevalence of
dengue cases will influence the predicative values. However, sen-
sitivity and specificity should be stable characteristics of the assay,
and up to 50% of fever presentations may be caused by dengue
infections (9, 20, 25). Another limitation is that the majority
(88%) of dengue virus specimens were frompatients with second-
ary infections. Due to the dominance of secondary infections in
settings where dengue is endemic, additional diagnostic studies
with patients with primary dengue infections are necessary, as
only one study has examined the accuracies of the Panbio Pan-E
(sensitivity, 63.7%) and the Bio-Rad Platelia (sensitivity, 73.6%)
NS1 antigen assays (18). Another potential limitation and source
of variation in this assessment is the use of a pediatric dengue
patient cohort and an adult dengue virus-negative patient cohort
to examine ELISA performance. Future investigations should ex-
amine potential differences in the NS1 antigen responses between
pediatric and adult dengue virus-positive patients and their effects
on diagnostic tests. Another limitation of the study was that infor-
mation on the number of days of illness prior to hospital admis-
sion was not available because of the requirements of the sample
anonymizing process, which meant that examination of the tem-
poral reactivity of the ELISAs was not possible. The above-men-
tioned issues highlight the problems in obtaining sufficient vol-
umes of well-characterized dengue virus-positive and -negative
specimens that are representative for geographical location, infec-
tion status, sample collection timing, infecting serotype, patient
sex and age, and severity of disease, and international cooperation
is required to address these issues. Another source of between-
study variation is the choice of the reference or gold standard
comparator. This study is one of the few evaluations of dengue
diagnostic performance that employed a composite final patient
diagnosis (i.e., dengue or not) using recognized reference meth-
ods. The use of a composite final patient diagnosis provides a
more real-life comparator than the use of only another diagnostic
method, whichmay have its own inherent diagnostic inaccuracies
or limitations.
From the results presented in this evaluation, it is clear that
ELISAs for single biomarkers such asNS1 antigen or IgMantibod-
ies have limitations when used individually due to temporal con-
siderations. However, when NS1 antigen and IgM antibody
ELISAs are used in combination, they yield acceptably high levels
of accuracy for the diagnosis of dengue infection across the entire
temporal spectrum of illness. Results presented here demonstrate
that both the Panbio and Standard Diagnostics NS1 antigen and
IgM antibody ELISAs, when using a combination of NS1 antigen
and IgM antibody biomarkers, provided acceptable levels of accu-
racy for dengue diagnosis; however, one should be wary of false
positivity caused by persistence of dengue virus IgM antibodies
from a previous infection. It is also recommended that consider-
ation be given to the appropriateness of the assays to be used. For
example, if there is only a small number of samples to be tested
and if the test is to be used in a low-resource setting, then the use
of dengue rapid immunochromatographic tests incorporating
NS1 antigen and IgM antibody should be considered as an alter-
native to ELISAs, as recent evaluations have demonstrated good
levels of accuracy for the rapid immunochromatographic test for-
mat (4). However, compared to rapid immunochromatographic
tests, the ELISA format has the benefit of being able to process a
relatively large number of samples at one time and also has the
benefit of nonsubjective reading using an ELISA plate reader.
Further investigations are required to determine the nature of
lot-to-lot variation of the ELISAs, as well as to develop assays that
can predict other important factors such as clinical severity to help
guide patient management.
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